Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Moodys
Express Scripts
Harvard Business School
Boehringer Ingelheim

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Crenezumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Crenezumab: Patents, clinical trial progress, indications

Crenezumab is an investigational drug.

There have been 8 clinical trials for Crenezumab. The most recent clinical trial was a Phase 1 trial, which was initiated on March 29th 2017.

The most common disease conditions in clinical trials are Alzheimer Disease and [disabled in preview]. The leading clinical trial sponsors are Genentech, Inc., Hoffmann-La Roche, and Banner Alzheimer's Institute.

There are five US patents protecting this investigational drug and forty-five international patents.

Recent Clinical Trials for Crenezumab
TitleSponsorPhase
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's DiseaseBanner Alzheimer's InstitutePhase 2
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's DiseaseGenentech, Inc.Phase 2
An Open-Label Crenezumab Study in Patients With Alzheimer's DiseaseHoffmann-La RochePhase 3

See all Crenezumab clinical trials

Clinical Trial Summary for Crenezumab

Top disease conditions for Crenezumab
Top clinical trial sponsors for Crenezumab

See all Crenezumab clinical trials

US Patents for Crenezumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Crenezumab   See Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   See Pricing
Crenezumab   See Pricing Bispecific chimeric antigen receptors and methods of use thereof to treat cancer Seattle Children's Hospital (Seattle, WA)   See Pricing
Crenezumab   See Pricing Method and composition for hyperthermally treating cells   See Pricing
Crenezumab   See Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   See Pricing
Crenezumab   See Pricing Detection of misfolded amyloid beta protein AMPRION, INC. (San Diego, CA) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Crenezumab

Drugname Country Document Number Estimated Expiration Related US Patent
Crenezumab Australia 2013220749 2032-02-15   See Pricing
Crenezumab Brazil 112014019627 2032-02-15   See Pricing
Crenezumab Canada 2862476 2032-02-15   See Pricing
Crenezumab China 104114705 2032-02-15   See Pricing
Crenezumab China 108570468 2032-02-15   See Pricing
Crenezumab European Patent Office 2814963 2032-02-15   See Pricing
Crenezumab India 5670DEN2014 2032-02-15   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Mallinckrodt
McKesson
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.